Current Rating and Its Significance
MarketsMOJO’s Strong Buy rating for Lupin Ltd. indicates a robust confidence in the company’s prospects based on a comprehensive evaluation of multiple factors. This rating suggests that the stock is expected to outperform the broader market and offers attractive potential returns for investors willing to hold the stock over the medium to long term. The upgrade to Strong Buy from Buy, effective 08 May 2026, was driven by improvements in the company’s overall Mojo Score, which rose from 74 to 80, reflecting enhanced fundamentals and market sentiment.
Here’s How Lupin Ltd. Looks Today
As of 16 May 2026, Lupin Ltd. continues to demonstrate solid financial health and operational strength. The stock has delivered a 9.78% return over the past year, outperforming many peers in the Pharmaceuticals & Biotechnology sector. Year-to-date, the stock has gained 7.67%, supported by positive quarterly results and steady investor interest. The one-day price change stands at +0.71%, indicating ongoing market confidence.
Quality Assessment
The company’s quality grade is classified as good, reflecting its strong operational metrics and consistent profitability. Lupin Ltd. maintains a low average debt-to-equity ratio of 0.11 times, underscoring prudent financial management and limited leverage risk. The firm has exhibited healthy long-term growth, with net sales increasing at an annual rate of 13.02% and operating profit expanding by 34.70%. This growth trajectory is supported by a track record of four consecutive quarters of positive results, signalling operational resilience and effective cost control.
Valuation Perspective
Valuation metrics for Lupin Ltd. are very attractive as of today. The company’s price-to-book value stands at 4.7, which is considered reasonable given its strong return on equity (ROE) of 25.7%. This valuation is particularly compelling when compared to peers, as the stock trades at a discount relative to historical averages within the sector. The price-to-earnings-to-growth (PEG) ratio is notably low at 0.2, indicating that the stock’s price does not fully reflect its earnings growth potential, making it an appealing option for value-conscious investors.
Financial Trend and Profitability
Financially, Lupin Ltd. is in a very positive phase. The company’s net profit has grown by 24.41%, with quarterly net sales reaching a record high of ₹7,474.66 crores and quarterly profit after tax (PAT) hitting ₹1,560.39 crores. The return on capital employed (ROCE) for the half-year period is an impressive 27.06%, highlighting efficient capital utilisation. These figures demonstrate Lupin’s ability to generate strong cash flows and maintain profitability even in a competitive pharmaceutical landscape.
Technical Outlook
From a technical standpoint, the stock is mildly bullish. While short-term price movements have seen some volatility, with a one-month decline of 2.79% and a one-week drop of 4.37%, the medium-term trend remains positive. Over the past six months, Lupin Ltd. has gained 10.65%, reflecting underlying strength and investor confidence. The technical grade supports the fundamental case, suggesting that the stock is well-positioned for further appreciation.
Institutional Confidence
Institutional investors hold a significant 47.03% stake in Lupin Ltd., signalling strong endorsement from market professionals who typically conduct rigorous fundamental analysis. This high level of institutional ownership often correlates with greater stock stability and liquidity, providing reassurance to retail investors about the company’s prospects.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Implications for Investors
For investors, the Strong Buy rating on Lupin Ltd. suggests a favourable risk-reward profile. The company’s strong fundamentals, attractive valuation, positive financial trends, and supportive technical indicators combine to create a compelling investment case. While the pharmaceutical sector can be subject to regulatory and competitive pressures, Lupin’s consistent growth and profitability provide a solid foundation for future gains.
Investors should consider Lupin Ltd. as a core holding within a diversified portfolio, particularly those seeking exposure to midcap pharmaceutical companies with robust growth prospects. The stock’s current discount to peers and strong institutional backing further enhance its appeal.
Summary
In summary, Lupin Ltd.’s Strong Buy rating by MarketsMOJO, last updated on 08 May 2026, is supported by a combination of good quality, very attractive valuation, very positive financial trends, and mildly bullish technicals. As of 16 May 2026, the company’s financial metrics and stock performance reinforce this positive outlook, making it a noteworthy candidate for investors aiming to capitalise on growth in the Pharmaceuticals & Biotechnology sector.
About Lupin Ltd.
Lupin Ltd. is a midcap company operating in the Pharmaceuticals & Biotechnology sector. It has demonstrated consistent growth in net sales and profits, backed by strong operational execution and financial discipline. The company’s strategic focus on innovation and market expansion continues to drive its competitive positioning.
Market Performance Snapshot (As of 16 May 2026)
1 Day Change: +0.71%
1 Week Change: -4.37%
1 Month Change: -2.79%
3 Month Change: +3.40%
6 Month Change: +10.65%
Year-to-Date Change: +7.67%
1 Year Change: +9.78%
Key Financial Metrics
Debt to Equity Ratio (Average): 0.11 times
Net Sales Growth (Annual): 13.02%
Operating Profit Growth: 34.70%
Net Profit Growth: 24.41%
ROCE (Half Year): 27.06%
ROE: 25.7%
Price to Book Value: 4.7
PEG Ratio: 0.2
Institutional Holdings: 47.03%
These figures collectively underpin the Strong Buy rating and highlight Lupin Ltd.’s position as a fundamentally sound and attractively valued stock in the current market environment.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
